SCOTTSDALE, AZ--(Marketwired - Dec 14, 2015) - Nutra Pharma Corp. (the "Company") (OTCQB: NPHC), a biopharmaceutical company engaged in the acquisition, licensing and marketing of homeopathic treatments and ethical drugs for the management of pain, neurological disorders, cancer, auto-immune and infectious diseases, today announces that it has engaged the Corporate Communications Services of QualityStocks. Based in Scottsdale, Arizona, QualityStocks has assisted more than 300 public companies with their efforts to broaden influence, attract growth capital and improve shareholder value over the past 9 years and 11 months.
"We are pleased to have engaged the services of QualityStocks and look forward to a long and fruitful relationship with them as we work to better communicate our progress with shareholders and the general public," said Nutra Pharma's chairman and CEO Rik Deitsch. "We believe that Nutra Pharma has an important role to play not only in the traditional ethical arena, but in the less-well-known homeopathic domain as well. We are committed to increasing corporate value through the continued discovery of revolutionary pharmaceutical treatments, expanded distribution reach, and general brand awareness."
Under the agreement, QualityStocks will strategically use its network of partners, daily and weekly newsletters, social media channels, blog and other outreach tools to relay Nutra Pharma's corporate message and progress to the investment community.
"QualityStocks enthusiastically welcomes Nutra Pharma," said Managing Director Michael McCarthy. "Nutra Pharma is one of those progressive pioneering companies that do more than sell products; their work makes our lives better. It is an honor to have the Nutra Pharma team on board and we look forward to helping the company reach its corporate communication goals."
About Nutra Pharma Corp.
Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain. Additionally, the Company markets drug products for sale for the treatment of pain under the brand Nyloxin® and Pet Pain-Away.
For more information on Nutra Pharma Corp, visit http://www.nutrapharma.com
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
To receive the latest updates on our clients and stocks we're watching, sign up for the QualityStocks Newsletter at http://Signup.QualityStocks.net
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.